news
Novel formulation could provide solution to cancer vaccine shortcomings
Researchers have developed a new formulation for cancer vaccines that could provide a solution to its delivery complications.
List view / Grid view
Preclinical Research
Filter the results
news
Funding for AI in drug development, clinical trials and information synthesis hits $5.2bn
A study has suggested that while funding for artificial intelligence in pharma was $5.2bn in 2019, overall investment is slowing.
news
Once-a-month oral contraceptive pill one step closer
A new slow-release formulation and delivery system for the oral contraceptive pill has shown success in pre-clinical trials and could be taken once a month.
news
Priority Review granted to pemigatinib for treatment of cholangiocarcinoma
The US FDA has awarded pemigatinib Priority Review, after the drug met its primary and secondary endpoints in a Phase II trial.
Whitepapers/App Notes/Posters
Whitepaper: The Use of Positron Emission Tomography (PET) in Pre-clinical Pharmaceutical Research
Positron emission tomography (PET) is a popular nuclear imaging technique used to gain information about specific metabolic functions.
news
Novartis could face legal action over Zolgensma application
The pharmaceutical company failed to inform the FDA of manipulated data when the gene therapy was under review and could face a legal battle.
news
Discoveries made through ‘routine’ research can now be patentable
In a ruling handed down on 27 March 2019 by the UK Supreme Court, Lord Hodge has confirmed that discoveries made through well-established or routine research protocols can be rewarded with a patent...
webinar
Advances in automated performance verification for UV/VIS spectrophotometers
22 August 2018 | By Mettler-Toledo
Regulated environments require performance verification (qualification) of UV/VIS spectrophotometers on a regular basis. Instrument performance is the main factor directly affecting the accuracy and repeatability of measurements. Hence, it is important that this is regularly monitored and that documentary evidence is provided. Optical performance verification is conducted to the widely…
Whitepapers/App Notes/Posters
Whitepaper: Why should you care about Burkholderia cepacia?
The Burkholderia cepacia complex (BCC) species are a group of gram-negative, rod-shaped bacteria that have been shown in recent years to be of concern for patients, and thus for manufacturers of drugs and products that contribute to patient health...
news
Anticancer drug nintedanib found to be effective against malignant pleural mesothelioma
Researchers have found that nintedanib shows promising effectiveness in halting the growth of human malignant pleural mesothelioma in preclinical models.
news
Robotic method isolates high-producing cell lines for HIV vaccine production
Technical advances in vaccine production should shorten the time to clinical trials, breaking the logjam of promising new candidate vaccines waiting to be tested...
news
Scientists identify bacterial link with oesophageal cancer
Researchers at NYU Langone Health's Perlmutter Cancer Center report that at least three kinds of bacteria in the mouths of Americans may directly affect their risk of developing oesophageal cancer.
news
Drugs taken before surgery may reduce metastatic recurrence
Researchers have identified a drug regimen administered prior to and after surgery that significantly reduces the risk of post-surgical cancer recurrence...
news
Collaboration is ‘game changer’ in delivering cell and gene therapies
Collaboration between the pharmaceutical industry, patients and health regulators will be a ‘game changer’ in delivering exciting new cell and gene therapies to treat conditions like cancer and vision loss.
article
Ensuring patient safety during clinical trials; translation to preclinical drug discovery
3 September 2012 | By David Cook & James Milligan, AstraZeneca
Ensuring patient safety during clinical trials is of paramount consideration with stringent monitoring built into trials (and beyond) and the design and interpretation of safety outcomes subject to a large amount of regulation. As a result, it is rare for clinical trials to produce extreme adverse drug reactions but it…